Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Avidity Biosciences (RNA) stocks in Canada

Learn how to easily invest in Avidity Biosciences stocks.

Avidity Biosciences is a biotechnology business based in the US. Avidity Biosciences stocks (RNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $24.42 – an increase of 10.21% over the previous week. Avidity Biosciences employs 125 staff and has a trailing 12-month revenue of around $9.3 million.

How to buy stocks in Avidity Biosciences

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Avidity Biosciences stock price (NASDAQ:RNA)

Use our graph to track the performance of RNA stocks over time.

Avidity Biosciences shares at a glance

Information last updated 2022-05-11.
Latest market close$13.60
52-week range$11.08 - $29.59
50-day moving average $17.11
200-day moving average $20.17
Wall St. target price$49.80
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.85

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Avidity Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Avidity Biosciences price performance over time

Historical closes compared with the close of $13.6 from 2022-05-16

1 week (2022-05-10) 11.48%
1 month (2022-04-13) N/A
3 months (2022-02-17) -10.94%
6 months (2021-11-17) -48.74%
1 year (2021-05-17) -34.99%
2 years (2020-05-13) N/A
3 years (2019-05-13) N/A
5 years (2017-05-13) N/A

Avidity Biosciences financials

Revenue TTM $9.3 million
Gross profit TTM $-91,856,000
Return on assets TTM -19.38%
Return on equity TTM -34.32%
Profit margin 0%
Book value $7.99
Market capitalisation $556.4 million

TTM: trailing 12 months

Avidity Biosciences share dividends

We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.

Avidity Biosciences overview

Avidity Biosciences, Inc. , a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site